Artigos de revistas sobre o tema "MuscleBlind Like (MBNL)"
Crie uma referência precisa em APA, MLA, Chicago, Harvard, e outros estilos
Veja os 50 melhores artigos de revistas para estudos sobre o assunto "MuscleBlind Like (MBNL)".
Ao lado de cada fonte na lista de referências, há um botão "Adicionar à bibliografia". Clique e geraremos automaticamente a citação bibliográfica do trabalho escolhido no estilo de citação de que você precisa: APA, MLA, Harvard, Chicago, Vancouver, etc.
Você também pode baixar o texto completo da publicação científica em formato .pdf e ler o resumo do trabalho online se estiver presente nos metadados.
Veja os artigos de revistas das mais diversas áreas científicas e compile uma bibliografia correta.
Bargiela, Ariadna, Maria Sabater-Arcis, Jorge Espinosa-Espinosa, Miren Zulaica, Adolfo Lopez de Munain e Ruben Artero. "Increased Muscleblind levels by chloroquine treatment improve myotonic dystrophy type 1 phenotypes in in vitro and in vivo models". Proceedings of the National Academy of Sciences 116, n.º 50 (21 de novembro de 2019): 25203–13. http://dx.doi.org/10.1073/pnas.1820297116.
Texto completo da fonteVoss, Dillon, Anthony Sloan, Eli Bar e Eli Bar. "TAMI-49. THE ALTERNATIVE SPLICING FACTOR MBNL1 INHIBITS GLIOBLASTOMA TUMOR INITIATION AND PROGRESSION BY REDUCING HYPOXIA-INDUCED STEMNESS". Neuro-Oncology 22, Supplement_2 (novembro de 2020): ii223—ii224. http://dx.doi.org/10.1093/neuonc/noaa215.936.
Texto completo da fonteOverby, Sarah, Estefanía Cerro-Herreros, Jorge Espinosa-Espinosa, Irene González-Martínez, Nerea Moreno, Juan Fernández-Costa, Jordina Balaguer-Trias et al. "BlockmiR AONs as Site-Specific Therapeutic MBNL Modulation in Myotonic Dystrophy 2D and 3D Muscle Cells and HSALR Mice". Pharmaceutics 15, n.º 4 (31 de março de 2023): 1118. http://dx.doi.org/10.3390/pharmaceutics15041118.
Texto completo da fonteYadava, Ramesh S., Mahua Mandal e Mani S. Mahadevan. "Studying the Effect of MBNL1 and MBNL2 Loss in Skeletal Muscle Regeneration". International Journal of Molecular Sciences 25, n.º 5 (26 de fevereiro de 2024): 2687. http://dx.doi.org/10.3390/ijms25052687.
Texto completo da fonteGonzález, Àlex L., Daniel Fernández-Remacha, José Ignacio Borrell, Jordi Teixidó e Roger Estrada-Tejedor. "Cognate RNA-Binding Modes by the Alternative-Splicing Regulator MBNL1 Inferred from Molecular Dynamics". International Journal of Molecular Sciences 23, n.º 24 (18 de dezembro de 2022): 16147. http://dx.doi.org/10.3390/ijms232416147.
Texto completo da fonteVerbeeren, Jens, Joana Teixeira e Susana M. D. A. Garcia. "The Muscleblind-like protein MBL-1 regulates microRNA expression in Caenorhabditis elegans through an evolutionarily conserved autoregulatory mechanism". PLOS Genetics 19, n.º 12 (22 de dezembro de 2023): e1011109. http://dx.doi.org/10.1371/journal.pgen.1011109.
Texto completo da fonteTerenzi, Fulvia, e Andrea N. Ladd. "Conserved developmental alternative splicing of muscleblind-like (MBNL) transcripts regulates MBNL localization and activity". RNA Biology 7, n.º 1 (janeiro de 2010): 43–55. http://dx.doi.org/10.4161/rna.7.1.10401.
Texto completo da fonteLópez-Martínez, Andrea, Patricia Soblechero-Martín, Laura de-la-Puente-Ovejero, Gisela Nogales-Gadea e Virginia Arechavala-Gomeza. "An Overview of Alternative Splicing Defects Implicated in Myotonic Dystrophy Type I". Genes 11, n.º 9 (22 de setembro de 2020): 1109. http://dx.doi.org/10.3390/genes11091109.
Texto completo da fonteSznajder, Łukasz J., e Maurice S. Swanson. "Short Tandem Repeat Expansions and RNA-Mediated Pathogenesis in Myotonic Dystrophy". International Journal of Molecular Sciences 20, n.º 13 (9 de julho de 2019): 3365. http://dx.doi.org/10.3390/ijms20133365.
Texto completo da fonteTanner, Matthew K., Zhenzhi Tang e Charles A. Thornton. "Targeted splice sequencing reveals RNA toxicity and therapeutic response in myotonic dystrophy". Nucleic Acids Research 49, n.º 4 (27 de janeiro de 2021): 2240–54. http://dx.doi.org/10.1093/nar/gkab022.
Texto completo da fonteLópez Castel, Arturo, Sarah Joann Overby e Rubén Artero. "MicroRNA-Based Therapeutic Perspectives in Myotonic Dystrophy". International Journal of Molecular Sciences 20, n.º 22 (9 de novembro de 2019): 5600. http://dx.doi.org/10.3390/ijms20225600.
Texto completo da fonteHolm, Frida, Eva Hellqvist, Cayla N. Mason, Shawn A. Ali, Nathaniel Delos-Santos, Christian L. Barrett, Hye-Jung Chun et al. "Reversion to an embryonic alternative splicing program enhances leukemia stem cell self-renewal". Proceedings of the National Academy of Sciences 112, n.º 50 (30 de novembro de 2015): 15444–49. http://dx.doi.org/10.1073/pnas.1506943112.
Texto completo da fonteHuang, Hu, Karl J. Wahlin, Minda McNally, Natasha D. Irving e Ruben Adler. "Developmental regulation of muscleblind-like (MBNL) gene expression in the chicken embryo retina". Developmental Dynamics 237, n.º 1 (janeiro de 2008): 286–96. http://dx.doi.org/10.1002/dvdy.21408.
Texto completo da fonteTabaglio, Tommaso, Diana HP Low, Winnie Koon Lay Teo, Pierre Alexis Goy, Piotr Cywoniuk, Heike Wollmann, Jessica Ho et al. "MBNL1 alternative splicing isoforms play opposing roles in cancer". Life Science Alliance 1, n.º 5 (7 de setembro de 2018): e201800157. http://dx.doi.org/10.26508/lsa.201800157.
Texto completo da fontePenna, Matthew S., Rong-Chi Hu, George G. Rodney e Thomas A. Cooper. "The role ofLimch1alternative splicing in skeletal muscle function". Life Science Alliance 6, n.º 6 (28 de março de 2023): e202201868. http://dx.doi.org/10.26508/lsa.202201868.
Texto completo da fonteXie, Jianxin, Wei Zou, Madina Tugizova, Kang Shen e Xiangming Wang. "MBL-1 and EEL-1 affect the splicing and protein levels of MEC-3 to control dendrite complexity". PLOS Genetics 19, n.º 9 (20 de setembro de 2023): e1010941. http://dx.doi.org/10.1371/journal.pgen.1010941.
Texto completo da fonteLi, Moyi, Yan Zhuang, Ranjan Batra, James D. Thomas, Mao Li, Curtis A. Nutter, Marina M. Scotti et al. "HNRNPA1-induced spliceopathy in a transgenic mouse model of myotonic dystrophy". Proceedings of the National Academy of Sciences 117, n.º 10 (21 de fevereiro de 2020): 5472–77. http://dx.doi.org/10.1073/pnas.1907297117.
Texto completo da fonteStepniak-Konieczna, Ewa, Patryk Konieczny, Piotr Cywoniuk, Julia Dluzewska e Krzysztof Sobczak. "AON-induced splice-switching and DMPK pre-mRNA degradation as potential therapeutic approaches for Myotonic Dystrophy type 1". Nucleic Acids Research 48, n.º 5 (22 de janeiro de 2020): 2531–43. http://dx.doi.org/10.1093/nar/gkaa007.
Texto completo da fonteWang, Eric T., Daniel Treacy, Katy Eichinger, Adam Struck, Joseph Estabrook, Hailey Olafson, Thomas T. Wang et al. "Transcriptome alterations in myotonic dystrophy skeletal muscle and heart". Human Molecular Genetics 28, n.º 8 (17 de dezembro de 2018): 1312–21. http://dx.doi.org/10.1093/hmg/ddy432.
Texto completo da fonteHolm, Frida Linnea, Eva Hellqvist, Cayla N. Mason, Shawn Ali, Nathaniel Delos Santos, Christian Barrett, Hye-Jung Chun et al. "Reversion to an Embryonic Alternative Splicing Program Enhances Leukemia Stem Cell Self-Renewal". Blood 126, n.º 23 (3 de dezembro de 2015): 1227. http://dx.doi.org/10.1182/blood.v126.23.1227.1227.
Texto completo da fonteIhsan, M. O., D. M. Tan, U. Muniasamy, M. S. Ong, X. Y. Lin, C. N. Lee, R. Dorajoo e V. Sorokin. "Muscleblind-like (MBNL) protein family overexpression lead to pro-synthetic phenotype modulation of arterial human vascular smooth muscle cells in diabetes mellitus". Atherosclerosis 355 (agosto de 2022): 205–6. http://dx.doi.org/10.1016/j.atherosclerosis.2022.06.821.
Texto completo da fonteJu, Woong, Hye Youn Sung e Jung-Hyuck Ahn. "Abstract B091: Overexpression of Muscleblind Like Splicing Regulator 2 (MBNL2) enhances cisplatin resistance in ovarian cancer". Molecular Cancer Therapeutics 22, n.º 12_Supplement (1 de dezembro de 2023): B091. http://dx.doi.org/10.1158/1535-7163.targ-23-b091.
Texto completo da fonteChen, Jiaorong, Jiaqi Wang, Jingyi Qian, Mengying Bao, Xin Zhang e Zheng Huang. "MBNL1 Suppressed Cancer Metastatic of Skin Squamous Cell Carcinoma Via by TIAL1/MYOD1/Caspase-9/3 Signaling Pathways". Technology in Cancer Research & Treatment 20 (1 de janeiro de 2021): 153303382096075. http://dx.doi.org/10.1177/1533033820960755.
Texto completo da fonteTran, Hélène, Nathalie Gourrier, Camille Lemercier-Neuillet, Claire-Marie Dhaenens, Audrey Vautrin, Francisco José Fernandez-Gomez, Ludovic Arandel et al. "Analysis of Exonic Regions Involved in Nuclear Localization, Splicing Activity, and Dimerization of Muscleblind-like-1 Isoforms". Journal of Biological Chemistry 286, n.º 18 (18 de março de 2011): 16435–46. http://dx.doi.org/10.1074/jbc.m110.194928.
Texto completo da fonteCheng, Albert W., Jiahai Shi, Piu Wong, Katherine L. Luo, Paula Trepman, Eric T. Wang, Heejo Choi, Christopher B. Burge e Harvey F. Lodish. "Muscleblind-like 1 (Mbnl1) regulates pre-mRNA alternative splicing during terminal erythropoiesis". Blood 124, n.º 4 (24 de julho de 2014): 598–610. http://dx.doi.org/10.1182/blood-2013-12-542209.
Texto completo da fonteSun, Xueqin, Xinghua Diao, Xiaolin Zhu, Xuexue Yin e Guangying Cheng. "Nanog-mediated stem cell properties are critical for MBNL3-associated paclitaxel resistance of ovarian cancer". Journal of Biochemistry 169, n.º 6 (18 de fevereiro de 2021): 747–56. http://dx.doi.org/10.1093/jb/mvab021.
Texto completo da fonteGates, Devika P., Leslie A. Coonrod e J. Andrew Berglund. "Autoregulated Splicing of muscleblind-like 1 (MBNL1) Pre-mRNA". Journal of Biological Chemistry 286, n.º 39 (9 de agosto de 2011): 34224–33. http://dx.doi.org/10.1074/jbc.m111.236547.
Texto completo da fonteCai, Jin, Ningchao Wang, Guanglan Lin, Haowei Zhang, Weidong Xie, Yaou Zhang e Naihan Xu. "MBNL2 Regulates DNA Damage Response via Stabilizing p21". International Journal of Molecular Sciences 22, n.º 2 (14 de janeiro de 2021): 783. http://dx.doi.org/10.3390/ijms22020783.
Texto completo da fonteLi, Yanbing, Min Zong, Xiaonan Guan, Xuejiao Wu, Guiling Ma, Yu Wei e Zhi Li. "MBNL1-AS1 Promotes Hypoxia-Induced Myocardial Infarction via the miR-132-3p/RAB14/CAMTA1 Axis". Oxidative Medicine and Cellular Longevity 2023 (4 de fevereiro de 2023): 1–12. http://dx.doi.org/10.1155/2023/3308725.
Texto completo da fonteYokoyama, Shingo, Yoshitaka Ohno, Tatsuro Egawa, Kazuya Ohashi, Rika Ito, Huascar Pedro Ortuste Quiroga, Tomohiro Yamashita e Katsumasa Goto. "MBNL1-Associated Mitochondrial Dysfunction and Apoptosis in C2C12 Myotubes and Mouse Skeletal Muscle". International Journal of Molecular Sciences 21, n.º 17 (2 de setembro de 2020): 6376. http://dx.doi.org/10.3390/ijms21176376.
Texto completo da fonteHao, Minqi, Kevan Akrami, Ke Wei, Carlos De Diego, Nam Che, Jeong-Hee Ku, James Tidball, Michael C. Graves, Perry B. Shieh e Fabian Chen. "Muscleblind-like 2 (Mbnl2) -deficient mice as a model for myotonic dystrophy". Developmental Dynamics 237, n.º 2 (21 de janeiro de 2008): 403–10. http://dx.doi.org/10.1002/dvdy.21428.
Texto completo da fonteSeachrist, Darcie D., Molly M. Hannigan, Natasha N. Ingles, Bryan M. Webb, Kristen L. Weber-Bonk, Peng Yu, Gurkan Bebek et al. "The transcriptional repressor BCL11A promotes breast cancer metastasis". Journal of Biological Chemistry 295, n.º 33 (23 de junho de 2020): 11707–19. http://dx.doi.org/10.1074/jbc.ra120.014018.
Texto completo da fonteTeplova, Marianna, e Dinshaw J. Patel. "Structural insights into RNA recognition by the alternative-splicing regulator muscleblind-like MBNL1". Nature Structural & Molecular Biology 15, n.º 12 (30 de novembro de 2008): 1343–51. http://dx.doi.org/10.1038/nsmb.1519.
Texto completo da fonteLee, Johanna E., e Thomas A. Cooper. "Pathogenic mechanisms of myotonic dystrophy". Biochemical Society Transactions 37, n.º 6 (19 de novembro de 2009): 1281–86. http://dx.doi.org/10.1042/bst0371281.
Texto completo da fonteRamon-Duaso, Carla, Thomas Gener, Marta Consegal, Cristina Fernández-Avilés, Juan José Gallego, Laura Castarlenas, Maurice S. Swanson et al. "Methylphenidate Attenuates the Cognitive and Mood Alterations Observed in Mbnl2 Knockout Mice and Reduces Microglia Overexpression". Cerebral Cortex 29, n.º 7 (27 de julho de 2018): 2978–97. http://dx.doi.org/10.1093/cercor/bhy164.
Texto completo da fonteBallester-Lopez, Alfonsina, Judit Núñez-Manchón, Emma Koehorst, Ian Linares-Pardo, Miriam Almendrote, Giuseppe Lucente, Nicolau Guanyabens et al. "Three-dimensional imaging in myotonic dystrophy type 1". Neurology Genetics 6, n.º 4 (21 de julho de 2020): e484. http://dx.doi.org/10.1212/nxg.0000000000000484.
Texto completo da fonteSmith, Kelly P., Meg Byron, Carol Johnson, Yigong Xing e Jeanne B. Lawrence. "Defining early steps in mRNA transport: mutant mRNA in myotonic dystrophy type I is blocked at entry into SC-35 domains". Journal of Cell Biology 178, n.º 6 (10 de setembro de 2007): 951–64. http://dx.doi.org/10.1083/jcb.200706048.
Texto completo da fonteHerrendorff, Ruben, Maria Teresa Faleschini, Adeline Stiefvater, Beat Erne, Tatiana Wiktorowicz, Frances Kern, Matthias Hamburger, Olivier Potterat, Jochen Kinter e Michael Sinnreich. "Identification of Plant-derived Alkaloids with Therapeutic Potential for Myotonic Dystrophy Type I". Journal of Biological Chemistry 291, n.º 33 (13 de junho de 2016): 17165–77. http://dx.doi.org/10.1074/jbc.m115.710616.
Texto completo da fonteNeault, Nafisa, Aymeric Ravel-Chapuis, Stephen D. Baird, John A. Lunde, Mathieu Poirier, Emiliyan Staykov, Julio Plaza-Diaz et al. "Vorinostat Improves Myotonic Dystrophy Type 1 Splicing Abnormalities in DM1 Muscle Cell Lines and Skeletal Muscle from a DM1 Mouse Model". International Journal of Molecular Sciences 24, n.º 4 (14 de fevereiro de 2023): 3794. http://dx.doi.org/10.3390/ijms24043794.
Texto completo da fonteLee, Kyung-Soon, Yi Cao, Hanna E. Witwicka, Susan Tom, Stephen J. Tapscott e Edith H. Wang. "RNA-binding Protein Muscleblind-like 3 (MBNL3) Disrupts Myocyte Enhancer Factor 2 (Mef2) β-Exon Splicing". Journal of Biological Chemistry 285, n.º 44 (13 de agosto de 2010): 33779–87. http://dx.doi.org/10.1074/jbc.m110.124255.
Texto completo da fonteNeault, Nafisa, Sean O’Reilly, Aiman Tariq Baig, Julio Plaza-Diaz, Mehrdad Azimi, Faraz Farooq, Stephen D. Baird e Alex MacKenzie. "High-throughput kinome-RNAi screen identifies protein kinase R activator (PACT) as a novel genetic modifier of CUG foci integrity in myotonic dystrophy type 1 (DM1)". PLOS ONE 16, n.º 9 (14 de setembro de 2021): e0256276. http://dx.doi.org/10.1371/journal.pone.0256276.
Texto completo da fonteGurunathan, Arun, Lana S. Itskovich, Jason Clark, Matthew Burwinkel, Nathan Salomonis, Meenakshi Venkatasubramanian, Kashish Chetal, Lynn Lee e Ashish R. Kumar. "MLL-Fusion Leukemia Dependence on MBNL1 Is Associated with Alternative Splicing of Oncogenic Proteins". Blood 132, Supplement 1 (29 de novembro de 2018): 3883. http://dx.doi.org/10.1182/blood-2018-99-112349.
Texto completo da fonteItskovich, Svetlana S., Jason Clark, James C. Mulloy, Matthew D. Disney e Ashish R. Kumar. "MBNL1 As a New Therapeutic Target in MLL-Fusion Gene Leukemia". Blood 126, n.º 23 (3 de dezembro de 2015): 462. http://dx.doi.org/10.1182/blood.v126.23.462.462.
Texto completo da fonteAngelbello, Alicia J., Suzanne G. Rzuczek, Kendra K. Mckee, Jonathan L. Chen, Hailey Olafson, Michael D. Cameron, Walter N. Moss, Eric T. Wang e Matthew D. Disney. "Precise small-molecule cleavage of an r(CUG) repeat expansion in a myotonic dystrophy mouse model". Proceedings of the National Academy of Sciences 116, n.º 16 (29 de março de 2019): 7799–804. http://dx.doi.org/10.1073/pnas.1901484116.
Texto completo da fonteSen, Supriya, Indrani Talukdar, Ying Liu, Joseph Tam, Sita Reddy e Nicholas J. G. Webster. "Muscleblind-like 1 (Mbnl1) Promotes Insulin Receptor Exon 11 Inclusion via Binding to a Downstream Evolutionarily Conserved Intronic Enhancer". Journal of Biological Chemistry 285, n.º 33 (2 de junho de 2010): 25426–37. http://dx.doi.org/10.1074/jbc.m109.095224.
Texto completo da fontedeLorimier, Elaine, Melissa N. Hinman, Jeremy Copperman, Kausiki Datta, Marina Guenza e J. Andrew Berglund. "Pseudouridine Modification Inhibits Muscleblind-like 1 (MBNL1) Binding to CCUG Repeats and Minimally Structured RNA through Reduced RNA Flexibility". Journal of Biological Chemistry 292, n.º 10 (27 de janeiro de 2017): 4350–57. http://dx.doi.org/10.1074/jbc.m116.770768.
Texto completo da fonteLueck, John D., Ami Mankodi, Maurice S. Swanson, Charles A. Thornton e Robert T. Dirksen. "Muscle Chloride Channel Dysfunction in Two Mouse Models of Myotonic Dystrophy". Journal of General Physiology 129, n.º 1 (11 de dezembro de 2006): 79–94. http://dx.doi.org/10.1085/jgp.200609635.
Texto completo da fonteLiu, Weifeng, Wenyuan Lin e Liangliang Yu. "Long non-coding RNA muscleblind like splicing regulator 1 antisense RNA 1 (LncRNA MBNL1-AS1) promotes the progression of acute myocardial infarction by regulating the microRNA-132-3p/SRY-related high-mobility-group box 4 (SOX4) axis". Bioengineered 13, n.º 1 (1 de janeiro de 2022): 1424–35. http://dx.doi.org/10.1080/21655979.2021.2018974.
Texto completo da fonteFrison-Roche, Charles, Célia Martin Demier, Steve Cottin, Jeanne Lainé, Ludovic Arandel, Marius Halliez, Mégane Lemaitre et al. "MBNL deficiency in motor neurons disrupts neuromuscular junction maintenance and gait coordination". Brain, 26 de outubro de 2024. http://dx.doi.org/10.1093/brain/awae336.
Texto completo da fonteHildebrandt, Ryan P., Kathryn R. Moss, Aleksandra Janusz-Kaminska, Luke A. Knudson, Lance T. Denes, Tanvi Saxena, Devi Prasad Boggupalli et al. "Muscleblind-like proteins use modular domains to localize RNAs by riding kinesins and docking to membranes". Nature Communications 14, n.º 1 (9 de junho de 2023). http://dx.doi.org/10.1038/s41467-023-38923-6.
Texto completo da fonte